The best choice for chemotherapy would be dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel:
Each given for 4 cycles 2 weeks apart:
With growth factor support
This regimen is supported by results of the CALGB 9741 study
For triple negative breast cancer and node positive disease:
The use of an anthracycline-containing regimen is favored compared to a non-anthracycline containing regimen
References
1. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439.
2. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA et al. Anthracyclines in early breast cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647-2655.